Q4 2019 Fulgent Genetics Inc Earnings Call
Fulgent Genetics, Inc. (NASDAQ:FLGT), which is in the healthcare business, and is based in United States, led the...
Fulgent Genetics, Inc.'s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic...
If you own shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) then it's worth thinking about how it contributes to the...
The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Vice President of Commercial Operations Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times.
Clovis Oncology, Inc. (NASDAQ: CLVS) popped 90 cents, or more than 10%, to $9.73 on 11.7 million shares Wednesday on no news. 3D Systems Corporation (NYSE: DDD) climbed 63 cents, or 5.3%, to $12.34 on 2.9 million shares Wednesday. Wednesday's move broke the stock out of a month-long wedge formation, and next resistance for the stock, which has nearly doubled in 5 months, is at $14.25.
Fulgent Genetics (NASDAQ:FLGT) reported Q4 results.Quarterly Results • Earnings per share were up 500% over the past year to $0.04, which in line with the estimate.• Revenue of $8,387,000 up by 47.68% from the same period last year, which missed the estimate of $8,510,000.Conference Call Details • Date: Mar 10, 2020• Time: 8:05 PM ETView more earnings on FLGT• Webcast URL: https://edge.media-server.com/mmc/p/suwtghgdRecent Stock Performance • 52-week high was at $20.60• 52-week low was at $4.71• Price action over last quarter: Up 17.22%Company Overview Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.See more from Benzinga * Afternoon Market Stats In 5 Minutes * 20 Communication Services Stocks Moving In Tuesday's Session * 20 Consumer Cyclical Stocks Moving In Tuesday's Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Fourth Quarter 2019 Results: Revenue totals $8.4 million, growing 48% year over yearBillable tests delivered total 13,977, growing 118% year over yearGross Margin improves more.
First Quarter 2020 Results: Revenue totals $7.8 million, growing 44% year over yearBillable tests delivered total 13,163, growing 75% year over yearGross Margin improves.
Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the scope of superlative returns.
NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Fulgent Genetics, Inc. (NASDAQ:FLGT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 4:30 ...
Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.
Zacks.com featured highlights include: AQN, IDN, FLGT and SMED
The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care.
Q1 2020 Fulgent Genetics Inc Earnings Call
Perthuis previously held the role of Vice President of Commercial Operations with Fulgent since joining the company in May of 2017. In his new role, Perthuis will continue to lead the company’s global sales organization and commercialization effort as the company focuses on both US and international expansion. “We are very pleased to promote Brandon to this new role,” said Ming Hsieh, Chairman and CEO of Fulgent Genetics.
On the call today, we have Ming Hsieh, Chief Executive Officer, Paul Kim, Chief Financial Officer, and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing its financial results is available in the Investor Relations section of the company's website, fulgentgenetics.com.
Fulgent’s NGS test will be one of the market’s first diagnostic tests for the COVID-19 virus developed based on NGS technology. Fulgent and MedScan will begin accepting specimens for testing this week from healthcare providers, clinics and reference labs.
The company is currently accepting samples directly to its BSL-2 certified lab in Temple City, California, versus previously accepting extracted RNA samples through third party laboratories. With the ability to offer end-to-end testing for COVID-19, Fulgent can more efficiently manage the demand it is seeing for both its RT-PCR and NGS tests for the virus. The company’s lab has the capacity to accept and process thousands of samples per day for COVID-19 testing alone.
The company is offering end-to-end processing, analysis and reporting for its COVID-19 tests through its BSL-2, CLIA-certified lab in Temple City, California. In addition, the EUA allows for the test to be used with nasal swab specimens which are either self-collected by patients at home or in a health care setting using an authorized at-home collection kit offered by a third party, when determined to be appropriate by a health care provider.